Cargando…
Apolipoprotein E polymorphism modulation of asymmetric dimethylarginine in hypertensive patients is determined by renal function
BACKGROUND: Endothelial dysfunction is considered an early step of atherosclerotic vascular disease. Asymmetric dimethylarginine (ADMA), the main endogenous inhibitor of nitric oxide synthase (NOS), plays a critical role in the process of atherosclerosis in a uremic environment. Increased plasma ADM...
Autores principales: | Marrocos, Mauro Sergio Martins, Teixeira, Andrei Alkmin, Quinto, Beata Marie, Carmona, Silmara de Melo, Kuniyoshi, Mariana, Rodrigues, Cassio Jose, Dalboni, Maria Aparecida, Manfredi, Silvia, Canziani, Maria Eugênia, Batista, Marcelo Costa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4719742/ https://www.ncbi.nlm.nih.gov/pubmed/26790728 http://dx.doi.org/10.1186/s12944-016-0182-y |
Ejemplares similares
-
Diversity of Apolipoprotein E genetic polymorphism significance on cardiovascular risk is determined by the presence of Metabolic Syndrome among hypertensive patients
por: Teixeira, Andrei Alkmim, et al.
Publicado: (2014) -
Association of IL-6 Polymorphism -174G/C and Metabolic Syndrome in Hypertensive Patients
por: Teixeira, Andrei Alkmim, et al.
Publicado: (2015) -
Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA)
por: Tain, You-Lin, et al.
Publicado: (2017) -
Asymmetric Dimethylarginine in COPD Exacerbation
por: Ozkarafakili, Mufide Arzu, et al.
Publicado: (2022) -
Asymmetric Dimethylarginine (ADMA) and Endothelial Dysfunction: Implications for Atherogenesis
por: Landim, Maurício Batista Paes, et al.
Publicado: (2009)